Office of Review Management
This article was originally published in Pharmaceutical Approvals Monthly
Acting Director Sandra Kweder, MD, succeeds former Acting Director Heidi Jolson, MD, who left the agency to become a consultant Jan. 26. Kweder is the fourth person to fill the position in the last six months; her appointment is temporary, according to FDA. Kweder is deputy director of the Office of Drug Evaluation I
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.